Caplin Point Laboratories witnessed a strong rally in its stock price on Thursday, surging over 5% after the company posted robust Q1 FY26 results. The stock opened at ₹1,900 and climbed as high as ₹2,040 intraday, compared to its previous close of ₹1,929.60.
The pharmaceutical firm reported a 23.2% year-on-year (YoY) increase in net profit, which stood at ₹152.8 crore, up from ₹124 crore in Q1 FY25. Revenue rose 11% YoY to ₹510 crore as compared to ₹459 crore in the same quarter last year.
Operating performance also remained strong, with EBITDA rising 17% YoY to ₹178 crore from ₹152 crore. EBITDA margin improved to 35%, up from 33%, highlighting the company’s strong cost controls and efficient operations.
The stock’s 52-week low stands at ₹1,452, while the high is ₹2,641. The market is now closely watching the company’s strategy for expanding its product pipeline and geographic reach in the coming quarters.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.